Drug Patent Watch
OCTOBER 16, 2024
One issue continues to loom large in healthcare: the skyrocketing costs of pharmaceuticals. This challenge has become a significant hurdle for managed healthcare organizations, patients, and policymakers alike.
Bio Pharma Dive
OCTOBER 16, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
OCTOBER 16, 2024
Dr. Alexander Fanaroff In this Friday’s PCT Grand Rounds, Alexander Fanaroff of the University of Pennsylvania will present “Rigorous Testing of Behavior Change Interventions: Lessons From the BE ACTIVE Randomized Clinical Trial.” The Grand Rounds session will be held on Friday, October 18, 2024, at 1:00 pm eastern. Fanaroff is an assistant professor of medicine at the University of Pennsylvania.
Bio Pharma Dive
OCTOBER 16, 2024
The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 16, 2024
(juanma hache/Getty Images) When we start to go gray depends a lot on genetics. Your first gray hairs usually appear anywhere between your twenties and fifties. For men, gray hairs normally start at the temples and sideburns. Women tend to start graying on the hairline, especially at the front.
Bio Pharma Dive
OCTOBER 16, 2024
The pharma’s lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 16, 2024
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Pharma Times
OCTOBER 16, 2024
There are around 55,100 new prostate cancer cases in the UK every year
Pharmaceutical Technology
OCTOBER 16, 2024
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.
pharmaphorum
OCTOBER 16, 2024
Pfizer partners with US biotech Triana Biomedicines in a deal focusing on molecular glue degraders that could be worth $1.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 16, 2024
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use AI and tech to transform the company.
pharmaphorum
OCTOBER 16, 2024
NIH study finds Bavarian Nordic's mpox vaccine is effective in adolescents, a particularly vulnerable group amid the ongoing outbreak
Pharmaceutical Technology
OCTOBER 16, 2024
bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deemed sufficiently novel and inventive.
ACRP blog
OCTOBER 16, 2024
Just when it seemed as if decentralized clinical trials (DCTs) were in danger of becoming “yesterday’s news” in light of all the attention being paid lately to applications of artificial intelligence in the clinical research enterprise, the tables have turned, if perhaps only briefly, thanks to the release of finalized new U.S. Food and Drug Administration (FDA) regulatory guidance on DCTs.
Pharmaceutical Technology
OCTOBER 16, 2024
Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the development and manufacturing of 177Lu-BetaBart.
Drug Patent Watch
OCTOBER 16, 2024
Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems.
Pharmaceutical Technology
OCTOBER 16, 2024
Synedgen has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop MIIST305.
pharmaphorum
OCTOBER 16, 2024
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens. The technology proved vital in aiding understanding of the evolution of and spread of virus in real time to inform public health measures, ultimately accelerating drug and vaccine development.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
OCTOBER 16, 2024
UroGen Pharma has received the NDA acceptance from the US FDA for UGN-102 (mitomycin) to treat bladder cancer.
XTalks
OCTOBER 16, 2024
Pfizer’s Hympavzi (marstacimab-hncq) has received approval from the US Food and Drug Administration (FDA) for treating hemophilia A or B in adults and adolescents aged 12 and older with factor VIII deficiency (hemophilia A) or factor IX deficiency (hemophilia B), who do not have inhibitors to these factors. Hympavzi is the first anti-tissue factor pathway inhibitor (anti-TFPI) approved in the US for hemophilia A or B, and it’s also the first hemophilia therapy to be administered via a pre-
Pharmaceutical Technology
OCTOBER 16, 2024
The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is set to grow from sales of $11.5bn in 2023 to $30.8bn in 2033.
pharmaphorum
OCTOBER 16, 2024
Discover effective strategies for commercialising oncology treatments for young adults with cancer, and learn how these targeted approaches can improve patient outcomes and access to innovative therapies.
Fierce Pharma
OCTOBER 16, 2024
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from Gilead Sciences, the company has presented strong results from three real-world studies of its bi-monthly injection for HIV prevention.
pharmaphorum
OCTOBER 16, 2024
The FDA starts priority review of GSK's gepotidacin, vying to become the first new-class antibiotic for uncomplicated urinary tract infections in over 20 years
Fierce Pharma
OCTOBER 16, 2024
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. | A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030.
pharmaphorum
OCTOBER 16, 2024
Despite efforts to raise diversity in clinical trials, a study in head and neck cancer found the trend in the US is going in the other direction.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
OCTOBER 16, 2024
While radiopharmaceuticals have attracted significant interest in recent years thanks to their cancer-fighting prowess, the unique makeup of the meds has presented a host of production challenges f | SpectronRx has inked an agreement to complete its first European radiolabeling plant at the Belgian Nuclear Research Center in Mol, Belgium. The facility will initially focus on the labeling of Actinium-225-based radiopharmaceuticals.
pharmaphorum
OCTOBER 16, 2024
Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.
Fierce Pharma
OCTOBER 16, 2024
Scilex Pharma may soon flee the nest after its parent company Scilex Holding’s board of directors granted permission to explore routes to maximize the company’s value. | Scilex Pharma may soon flee the nest after its parent company Scilex Holding’s board of directors granted permission to explore alternative routes for the drugmaker.
pharmaphorum
OCTOBER 16, 2024
Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD)
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
110 
Let's personalize your content